Sp1127
HARNESSING THE GUT MICROBIOME TO TREAT HUMAN DISEASE
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
This session showcases the pioneering work done by the MMT section mentor awardee Dr. Justin Sonnenburg and his mentees who are leading independent programs focused on the intersection of diet-microbe-host physiology.
This session showcases the pioneering work done by the MMT section mentor awardee Dr. Justin Sonnenburg and his mentees who are leading independent programs focused on the intersection of diet-microbe-host physiology.
Presenter
Tracks
Related Products
UNBIASED MAPPING OF GUT MICROBIAL PATHWAYS THAT CONTRIBUTE TO INTESTINAL HEALTH
BACKGROUND AND AIMS: Peptostreptococcus stomatis (_P. stomatis_) is an enriched bacterium in colorectal cancer (CRC) patients as compared to healthy subjects in multiple cohorts. However, the potential role of _P. stomatis_ in colorectal tumorigenesis remains obscure…
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
